Drugs / MesemCart
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06981741 | Nov 2025 → Nov 2027 expected | articular cartilage disorder | BIONCaRT GmbH | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MesemCart | “investigational product - mesenchymal stromal cells (MSCs) derived from umbilical cord tissue (MesemCart) - will be applied once directly to the cartilage defect” NCT06981741 ↗ |
| Modality | Cell therapy | “mesenchymal stromal cells (MSCs) derived from umbilical cord tissue (MesemCart)” NCT06981741 ↗ |
| Route | Other | “will be applied once directly to the cartilage defect” NCT06981741 ↗ |